Glioma (Any Grade) in the Brain
Conditions
Brief summary
Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \[68Ga\]-DOTA-HK-011 in inflammation imaging of glioma.
Interventions
None listed
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Voluntary subjects, patients, or their legal representatives must sign the informed consent form. * There are no restrictions on the gender of volunteers; age must be between 18 and 75 years, inclusive. * Other imaging examination methods (e.g., CT, MRI) show the presence of intracranial lesions. * Patients with brain glioma who are scheduled for surgery or biopsy that will provide final pathological results. * Patients must have a kidney GFR \> 50 mL/min, ERPF \> 280 mL/min, platelet count (PLT) \> 75,000/μL, white blood cell count (WBC) \> 3,000/μL, and alanine aminotransferase (ALT) and asparta.
Exclusion criteria
* Individuals with a history of allergy to drugs with similar chemical or biological components to TSPO, a history of atopy, or currently suffering from allergic diseases. * Individuals currently participating in other drug clinical studies, or who have previously participated in any drug (excluding vitamins and minerals) clinical studies. * Individuals with other difficult-to-control clinical conditions, such as HIV infection, hepatitis C virus infection, active hepatitis B, other severe chronic infections, or serious mental, neurological, cardiovascular, respiratory, or other systemic diseases. * Red blood cell count (RBC) \< 4×10\^12/L, white blood cell count (WBC) \< 3×10\^9/L, hemoglobin \< 110 g/L, platelet count (PLT) \< 75×10\^9/L. * Significant liver and kidney function abnormalities, glomerular filtration rate (GFR) \< 50 ml/min. * Tumor burden involving more than 50% of the affected organ, or significant spinal cord compression. * Expected survival time less than six months, or having received chemotherapy within the past six months. * Individuals with severe acute comorbidities or severe refractory mental disorders. * Pregnant or breastfeeding women (pregnancy defined as a positive urine pregnancy test). * Individuals whose physical condition is unsuitable for radioactive examination. * Other circumstances deemed unsuitable for participation in the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax of lesion uptake value | Time Frame: 60min after administration |
Contacts
Primary ContactFeng Wang
Outcome results
None listed